Drug intelligence / Profile preview

SL-T10

Development stage: Phase 1
Lead developer: SL VaxiGen
Modality: Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Small Molecules, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Unknown (not Explicitly Stated; Likely Parenteral/intramuscular Based On Typical Administration For Dna Vaccines)

Overview

SL-T10 is a DNA-based therapeutic cancer vaccine developed by SL VaxiGen for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It functions as an immunostimulant, aiming to activate the immune system against prostate cancer cells. The drug is currently in Phase 1 clinical trials and has been studied both as a monotherapy and in combination with other agents such as GX-I7 and pembrolizumab. Its primary mechanism involves stimulating an immune response to target tumor cells[1][2][3][4][5].

Beyond the preview

Go deeper on SL-T10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SL-T10.

Explore the full profile